Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma - Contacts and Locations

Home

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma

This study has been completed.

Study NCT00020462. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00020462

Locations


United States, Maryland
	Medicine Branch
	Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

NCI - Center for Cancer Research-Medical Oncology

Investigators


Study Chair:	Sattva S. Neelapu, MD	NCI - Center for Cancer Research-Medical Oncology